GBC AG cuts MustGrow Biologics price target to CAD 2.51, keeps Buy
GBC AG lowered its target from CAD 2.70 and reiterated a Buy rating on MustGrow Biologics. It also cut FY2026 revenue forecast to CAD 3.5 million from CAD 4.5 million.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.